Atsushi Sakuraba (A Sakuraba)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 29

Top Topics

Systematic Review

Top Venues

Alimentary pharmacology & therapeutics

Annals of the rheumatic diseases

Annals of medicine

Journal of gastroenterology and hepatology

This page only lists publications with an associated author ORCID identifier.

Publications

Yusuke Miyatani, Yuga Komaki, Fukiko Komaki, Dejan Micic, Kian Keyashian, Atsushi Sakuraba
Factors associated with long-term clinical outcome in microscopic colitis. Annals of medicine 56 (1) (2024)
Yusuke Miyatani, Yuga Komaki, Fukiko Komaki, Dejan Micic, Kian Keyashian, Atsushi Sakuraba
Factors associated with long-term clinical outcome in microscopic colitis. Annals of medicine 56 (1) (2024)
Yusuke Miyatani, Yuga Komaki, Fukiko Komaki, Dejan Micic, Kian Keyashian, Atsushi Sakuraba
Factors associated with long-term clinical outcome in microscopic colitis. Annals of medicine 56 (1) (2024)
Tenzin Choden, Hui Zhang, Atsushi Sakuraba
Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease. Annals of medicine 55 (1) (2023)
Atsushi Sakuraba, Alexander Luna, Dejan Micic
A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients. Viruses 14 (8) (2022)
David Obadina, Haider Haider, Dejan Micic, Atsushi Sakuraba
Older Age at First Screening Colonoscopy is Associated With an Increased Risk of Colorectal Adenomas and Cancer. Journal of clinical gastroenterology (2022)
Sujaata Dwadasi, Maryam Zafer, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D Cohen, Joel Pekow, David T Rubin, Atsushi Sakuraba, Dejan Micic
Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflammatory bowel diseases 27 (10) (2022)
Atsushi Sakuraba, Alexander Luna, Dejan Micic
Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. Journal of hematology & oncology 15 (1) (2022)
Joseph Runde, Amarachi Erondu, Shintaro Akiyama, Cindy Traboulsi, Victoria Rai, Laura R Glick, Yangtian Yi, Jacob E Ollech, Russell D Cohen, Kinga B Skowron, Roger D Hurst, Konstatin Umanskiy, Benjamin D Shogan, Neil H Hyman, Michele A Rubin, Sushila R Dalal, Atsushi Sakuraba, Joel Pekow, Eugene B Chang, David T Rubin
Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis. Inflammatory bowel diseases 28 (9) (2022)
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Lee. Annals of the rheumatic diseases (2021)
Maryam Zafer, Hui Zhang, Sujaata Dwadasi, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D Cohen, Joel Pekow, David T Rubin, Atsushi Sakuraba, Dejan Micic
A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohn's & colitis 360 4 (1) (2021)
Maryam Zafer, Hui Zhang, Sujaata Dwadasi, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D Cohen, Joel Pekow, David T Rubin, Atsushi Sakuraba, Dejan Micic
A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohn's & colitis 360 4 (1) (2021)
Shintaro Akiyama, Akihiro Yamada, Jacob E Ollech, Yuga Komaki, Fukiko Komaki, Joel Pekow, Sushila R Dalal, Russell D Cohen, David T Rubin, Atsushi Sakuraba
Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. Journal of gastroenterology and hepatology 36 (10) (2021)
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Yang et al. Annals of the rheumatic diseases (2021)
Jingzhou Wang, Christopher Kaperak, Toshiro Sato, Atsushi Sakuraba
COVID-19 reinfection: a rapid systematic review of case reports and case series. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 69 (6) (2021)
Thomas X Lu, Matthew Dapas, Erika Lin, Trevor Peters, Atsushi Sakuraba
The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut 70 (11) (2020)
A Anyane-Yeboa, T Sato, Atsushi Sakuraba
Racial disparities in COVID-19 deaths reveal harsh truths about structural inequality in America. Journal of internal medicine 288 (4) (2020)
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
Response to 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Gremese et al. Annals of the rheumatic diseases (2020)
Jingzhou Wang, Joshua Prenner, Wenfei Wang, Atsushi Sakuraba, Neil Hyman, Sushila Dalal, Roger Hurst, Russell D Cohen, Konstantin Umanskiy, Benjamin D Shogan, Lindsay Alpert, David T Rubin, Janice Colwell, Joel Pekow
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 51 (12) (2020)
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
Response to 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Shi et al. Annals of the rheumatic diseases (2020)
Akihiro Yamada, Jingzhou Wang, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba
Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Alimentary pharmacology & therapeutics 50 (4) (2019)
Yunwei Wang, Jennifer Wang, Joel Pekow, Sushila Dalal, Russell D Cohen, Jacob Ollech, Amanda Israel, Benjamin D Shogan, Dejan Micic, Lisa Cannon, Konstantin Umanskiy, Roger Hurst, Neil Hyman, David T Rubin, Atsushi Sakuraba
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. Journal of gastroenterology and hepatology 34 (12) (2019)
Jacob E Ollech, Sujaata Dwadasi, Victoria Rai, Noam Peleg, Inessa Normatov, Amanda Israel, Philip H Sossenheimer, Britt Christensen, Joel Pekow, Sushila R Dalal, Atsushi Sakuraba, Russell D Cohen, David T Rubin
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Alimentary pharmacology & therapeutics 51 (6) (2019)
Adjoa Anyane-Yeboa, Akihiro Yamada, Haider Haider, Yunwei Wang, Yuga Komaki, Fukiko Komaki, Joel Pekow, Sushila Dalal, Russell D Cohen, Lisa Cannon, Konstantin Umanskiy, Radhika Smith, Roger Hurst, Neil Hyman, David T Rubin, Atsushi Sakuraba
A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Alimentary pharmacology & therapeutics 48 (9) (2018)
Yuga Komaki, Fukiko Komaki, Dejan Micic, Akihiro Yamada, Yasuo Suzuki, Atsushi Sakuraba
Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. Journal of gastroenterology and hepatology 32 (6) (2017)
Y Komaki, A Yamada, F Komaki, Atsushi Sakuraba
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply. Alimentary pharmacology & therapeutics 46 (9) (2017)
Ashwin N Ananthakrishnan, Atsushi Sakuraba, E L Barnes, J Pekow, L Raffals, M D Long, R S Sandler
The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Alimentary pharmacology & therapeutics 46 (2) (2017)
Y Komaki, A Yamada, F Komaki, D Micic, A Ido, Atsushi Sakuraba
Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Alimentary pharmacology & therapeutics 45 (8) (2017)
Y Komaki, A Yamada, F Komaki, D Micic, A Ido, Atsushi Sakuraba
Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. Alimentary pharmacology & therapeutics 45 (10) (2017)
Atsushi Sakuraba, Yasushi Iwao, Katsuyoshi Matsuoka, Makoto Naganuma, Haruhiko Ogata, Takanori Kanai, Toshifumi Hibi
Endoscopic and pathologic changes of the upper gastrointestinal tract in Crohn's disease. BioMed research international 2014 (2014)